India continues to reform biopharma regulatory processes and widen digitization efforts. The regulator will curb "re-deliberations" at subject expert committee meetings unless applicants furnish new data.
L to R: Anil Matai, Director General OPPI; Vinod Kotwal Member Secretary, NPPA; Bhushan Akshikar, MD, GSK Pharmaceuticals; Anupriya Singh Patel, Union Minister Of State For Health And Family Welfare, Dr Arunish Chawla, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers; DCGI Dr Rajeev Raghuvanshi; and Amitabh Dube, country president and MD, Novartis in India.
